What have been the investments and progress in your Lonavla facility so far?
RMS Regrow endeavors to ensure that all its facilities meet the highest quality standards and are properly accredited. Within two years of operation we have acquired ISO:13485, GMP, GLP and GCP certifications, which have enabled the company to advance its autologous cellular therapies particularly in cartilage and bone regeneration.

What do you think differentiates RMS Regrow from other stem cell based enterprises?
The treatment offered by RMS Regrow is much competitive as compared to other similar treatments like hip and knee Replacement. We believe in long term benefits to the patients and a scenario of higher quality of life with increased productivity and efficiency in the healthcare system. RMS Regrow has taken a conscious effort to deal with autologous therapies, where we have more 500 case studies of specific indications for more than three years. We have post marketing surveillance data where phase II and phase III clinical trials were done with a success rate of more than 98 percent.

What according to you should be some of the corrective steps to be taken by stakeholders to improve the present situation of regenerative medicine?
There is no doubt that we are on the edge of a major stem cell breakthrough. Doctors and hospitals should come forward to support stem cell therapies, companies and laboratories, which follow proper ethics and regulations in terms of patient safety and efficacy with proven technology that has been accepted in the developed countries.